ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Premium IconPremium Help Menu
S&P 500
6,033.11
0.94%
US Tech 100
21,355.20
1.31%
Dow Jones
42,515.09
0.75%
Brent Oil
71.76
-4.15%
Bitcoin
108,671.82
2.94%
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Cardiol Therapeutics Inc (CRDL) Quote

Cardiol Therapeutics Inc

Cardiol Therapeutics Inc (CRDL)

Cordel Group Plc
Cardiol Therapeutics Inc
1.43
-0.03
(-2.05%)
At close: June 16 4:00PM
15 min delayed - Upgrade to Realtime
1.43
0.00
( 0.00% )
After Hours: 4:30PM
15 min delayed - Upgrade to Realtime

Professional-Grade Tools, for Individual Investors.

Premium

Key stats and details

Current Price
1.43
Bid
1.43
Ask
1.49
Volume
114,519
1.42 Day's Range 1.49
0.7709 52 Week Range 2.63
Market Cap
118.189M
Previous Close
1.46
Open
1.48
Last Trade
7
@
1.49
Last Trade Time
17:18:16
Financial Volume
$ 165,504
VWAP
1.4452
Average Volume (3m)
198,741
Shares Outstanding
82,649,725
Dividend Yield
-
PE Ratio
-4.35
Earnings Per Share (EPS)
-0.44
Revenue
-
Net Profit
-36.68M

About Cardiol Therapeutics Inc

Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. The Company's lead drug candidate, CardiolRxTM (cannabidiol) oral solut... Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. The Company's lead drug candidate, CardiolRxTM (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease. It is recognized that cannabidiol inhibits activation of the inflammasome pathway, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with myocarditis, pericarditis, and heart failure. Show more

Sector
Coml Physical, Biologcl Resh
Industry
Coml Physical, Biologcl Resh
Headquarters
Oakville, Ontario, Can
Founded
-
Cardiol Therapeutics Inc is listed in the Coml Physical, Biologcl Resh sector of the NASDAQ with ticker CRDL. The last closing price for Cardiol Therapeutics was $1.46. Over the last year, Cardiol Therapeutics shares have traded in a share price range of $ 0.7709 to $ 2.63.

Cardiol Therapeutics currently has 82,649,725 shares outstanding. The market capitalization of Cardiol Therapeutics is $120.67 million. Cardiol Therapeutics has a price to earnings ratio (PE ratio) of -4.35.

Ask ADVFN Intelligence (AI)

CRDL Latest News

More News

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Edgar (US Regulatory)
May 14 2025
CRDL (-2.05%)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Edgar (US Regulatory)
April 29 2025
CRDL (-2.05%)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Edgar (US Regulatory)
April 28 2025
CRDL (-2.05%)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Edgar (US Regulatory)
April 16 2025
CRDL (-2.05%)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Edgar (US Regulatory)
April 01 2025
CRDL (-2.05%)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Edgar (US Regulatory)
March 14 2025
CRDL (-2.05%)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Edgar (US Regulatory)
March 03 2025
CRDL (-2.05%)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Edgar (US Regulatory)
February 20 2025
CRDL (-2.05%)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Edgar (US Regulatory)
February 04 2025
CRDL (-2.05%)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.01-0.6944444444441.441.51.35362314951.44013358CS
40.3431.19266055051.091.51.0382400041.31969785CS
120.326.54867256641.131.50.77091987411.13096735CS
260.1410.85271317831.291.510.77092407151.21165467CS
52-1.07-42.82.52.630.77093265171.66727426CS
1560.075.147058823531.363.120.452602141.46493746CS
260-1.2-45.62737642592.634.960.453212321.95910483CS

CRDL - Frequently Asked Questions (FAQ)

What is the current Cardiol Therapeutics share price?
The current share price of Cardiol Therapeutics is $ 1.43
How many Cardiol Therapeutics shares are in issue?
Cardiol Therapeutics has 82,649,725 shares in issue
What is the market cap of Cardiol Therapeutics?
The market capitalisation of Cardiol Therapeutics is USD 120.67M
What is the 1 year trading range for Cardiol Therapeutics share price?
Cardiol Therapeutics has traded in the range of $ 0.7709 to $ 2.63 during the past year
What is the PE ratio of Cardiol Therapeutics?
The price to earnings ratio of Cardiol Therapeutics is -4.35
What is the reporting currency for Cardiol Therapeutics?
Cardiol Therapeutics reports financial results in CAD
What is the latest annual profit for Cardiol Therapeutics?
The latest annual profit of Cardiol Therapeutics is CAD -36.68M
What is the registered address of Cardiol Therapeutics?
The registered address for Cardiol Therapeutics is 2265 UPPER MIDDLE ROAD EAST, SUITE 602, OAKVILLE, ONTARIO, L6H 0C3
Which industry sector does Cardiol Therapeutics operate in?
Cardiol Therapeutics operates in the COML PHYSICAL, BIOLOGCL RESH sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
JZJianzhi Education Technology Group Company Ltd
$ 5.43
(89.86%)
2.84M
SLRXSalarius Pharmaceuticals Inc
$ 1.02
(63.17%)
10.23M
RELIReliance Global Group Inc
$ 1.69
(43.22%)
2.55M
XTIAXTI Aerospace Inc
$ 3.87
(39.71%)
809.96k
INEOINNEOVA Holdings Ltd
$ 1.54
(38.74%)
4.02M
RUNSunrun Inc
$ 6.99
(-27.49%)
3.36M
SEDGSolarEdge Technologies Inc
$ 18.50
(-22.85%)
573.48k
ENPHEnphase Energy Inc
$ 38.68
(-15.78%)
584.83k
LSELeishen Energy Holding Company Ltd
$ 5.63
(-15.59%)
79.54k
CDTGCDT Environmental Technology Investment Holdings Ltd
$ 1.16
(-15.41%)
230.76k
GTIGraphjet Technology
$ 0.0805
(5.09%)
35.95M
GNLNGreenlane Holdings Inc
$ 0.0124
(0.00%)
33.24M
HCTIHealthcare Triangle Inc
$ 0.0256
(-3.03%)
28.13M
SLRXSalarius Pharmaceuticals Inc
$ 1.02
(63.17%)
10.23M
TDTHTrident Digital Tech Holdings Ltd
$ 0.293
(19.84%)
8.64M

CRDL Discussion

View Posts
Monksdream Monksdream 2 months ago
CRDL, new 52 week low
👍️0
Monksdream Monksdream 3 months ago
CRDL, new 52 week low
👍️0
Monksdream Monksdream 3 months ago
CRDL, under $2
👍️0
Monksdream Monksdream 4 months ago
CRDL, new 52 week low
👍️0
Monksdream Monksdream 6 months ago
CRDL, under $2
👍️0
MahinAgency MahinAgency 7 months ago
NASDAQ: $CRDL SHORT SQUEEZE ALERTS

Financial Strategy: With about $21 million in cash, the company may consider a small capital raise if new data boosts the stock price, aiming for a target of $10 per share (C$13.60
👍️0
MahinAgency MahinAgency 7 months ago
NASDAQ: $CRDL

Cardiol Therapeutics MAvERIC-Pilot Study Results:

Safety: High tolerability and 95% compliance.

Next Steps: Data supports advancing to Phase II/III MAVERIC-2 and Phase III MAVERIC-3 trials
👍️0
MahinAgency MahinAgency 7 months ago
A target of $10 per share (approximately C$13.60) is proposed, indicating a potential upside of over 5x within a year, contingent on strong data readouts for CardiolRx™?
👍️0
MahinAgency MahinAgency 7 months ago
NASDAQ: $CRDL

Advancement: Results support Phase II/III MAVERIC-2 and Phase III MAVERIC-3 trials, expanding accessibility to non-immunosuppressive oral therapy.

Short Squeeze Alerts $CRDL, BIG OPPORTUNITY
👍️0
MahinAgency MahinAgency 7 months ago
NASDAQ: $CRDL

Cardiol Therapeutics sets a 12-month price target of $10, valuing CardiolRx at $9 for recurrent pericarditis and $1 for acute myocarditis, based on projected sales and associated probabilities.
👍️0
MahinAgency MahinAgency 7 months ago
NASDAQ: $CRDL Pick Up This Morning Short Sueeze Aler

 MAvERIC-Pilot Results:
Safety: High tolerance, 95% compliance.
Next Steps: Advancing to Phase II/III MAVERIC-2 and Phase III MAVERIC-3 trials
👍️0
MahinAgency MahinAgency 7 months ago
NASDAQ: $CRDL MAvERIC-Pilot Study:

Efficacy: Significant reductions in pericarditis pain (mean score 5.8 to 1.5) and inflammation (CRP normalized in 80% of patients). Episodes dropped from 5.8/year to 0.9 during the trial.

👍️0
MahinAgency MahinAgency 7 months ago
Cardiol Therapeutics' Phase II MAvERIC-Pilot Clinical Results in Recurrent Pericarditis Presented at the American Heart Association Scientific Sessions 2024
👍️0
MahinAgency MahinAgency 7 months ago
INSIDER BUYING : Cardiol CEO David Elsley purchased approximately $100,000 in shares at about $2.03 each, indicating strong personal conviction in the company's potential.
👍️0
MahinAgency MahinAgency 7 months ago
$CRDL Here are the MAvERIC-Pilot study results that we’ve been waiting for! 

❤️Marked and rapid reductions in both pericarditis pain and inflammation  maintained throughout the 26-week study!

❤️Episodes of pericarditis per year substantially reduced 

❤️MAvERIC-Pilot results support advancing CardiolRx™ into the Phase II/III MAVERIC-2
and the Phase III MAVERIC-3 clinical trials

Congratulations to all long term shareholders! 
👍️0
MahinAgency MahinAgency 7 months ago
NASDAQ: $CRDL BIG NEWS:

Cardiol Therapeutics' Phase II MAvERIC-Pilot Clinical Results in Recurrent Pericarditis Presented at the American Heart Association Scientific Sessions 2024
👍️0
MahinAgency MahinAgency 7 months ago
Breaking News: NASDAQ: $CRDL unveils groundbreaking results for CardiolRx™ at the American Heart Association Conference! 📷 Rapid pain relief, 85% fewer recurrences, and lasting inflammation reduction.
👍️0
MahinAgency MahinAgency 7 months ago
NASDAQ: $CRDL 12-Month Price Target: $10 based on a sum-of-the-parts valuation.

Valued at $9 per share, assuming $609M in sales

Valued at $1 per share, assuming $132M in sales
👍️0
MahinAgency MahinAgency 7 months ago
NASDAQ: $CRDL RED TO GREEN, Looks Good

Cardiol Therapeutics Inc Today at 11:15am EST Dr. Allen Luis MayoClinic will present the Pericarditis full clinical data at #AHA2024
👍️0
MahinAgency MahinAgency 7 months ago
NASDAQ: $CRDL SHORT SQUEEZE ALERTS, STAY TUNED

Addressing urgent unmet medical needs: CardiolRx™ targets acute myocarditis, a life-threatening condition with no FDA-approved treatments
👍️0
MahinAgency MahinAgency 7 months ago
NASDAQ: $CRDL 12-Month Price Target: $10 based on a sum-of-the-parts valuation.

 Valued at $9 per share, assuming $609M in sales by 2033

Valued at $1 per share, assuming $132M in sales by 2033
👍 1
MahinAgency MahinAgency 7 months ago
NASDAQ: $CRDL The 12-month price target is $10, with $9 attributed to recurrent pericarditis and $1 to acute myocarditis

Recently raised $13.5 million to fund developments?, SHORT SQUEEZE ALERTS
👍️0
MahinAgency MahinAgency 7 months ago
NASDAQ: $CRDL lets See Red To Green, 

H.C. Wainwright maintains a "Buy" rating for Cardiol Therapeutics with a price target of $9.00.

The company recently raised $13.5 million
👍️0
MahinAgency MahinAgency 7 months ago
NASDAQ: $CRDL The company recently raised $13.5 million, ensuring financial backing for ongoing clinical developments and corporate growth
👍️0
MahinAgency MahinAgency 7 months ago
Picked up NASDAQ: $CRDL this morning…low float runner on news incoming… Short Squeeze Alerts

The 12-month price target is $10, with $9 attributed to recurrent pericarditis and $1 to acute myocarditis
👍️0
tw0122 tw0122 7 months ago
30 million shares offering at .26 October 30th
👍️0
MahinAgency MahinAgency 7 months ago
H.C. Wainwright maintains a "Buy" rating for Cardiol Therapeutics with a price target of $9.00.

MAVERIC-2 trial aims to assess CardiolRx in recurrent pericarditis patients post-IL-1 blocker therapy.
👍️0
MahinAgency MahinAgency 7 months ago
$CRDL up over 220% year-to-date; analysts raised the price target from $4.50 to $11.00, keeping a "Speculative Buy" rating.
👍️0
MahinAgency MahinAgency 7 months ago
NASDAQ: $CRDL SHORT SQUEEZE ALERTS

H.C. Wainwright maintains a "Buy" rating for Cardiol Therapeutics with a price target of $9.00.

MAVERIC-2 trial aims to assess CardiolRx in recurrent pericarditis patients post-IL-1 blocker therapy.
👍️0
MahinAgency MahinAgency 7 months ago
NASDAQ: $CRDL Financial Strategy: With about $21 million in cash, the company may consider a small capital raise if new data boosts the stock price,aiming for a target of $10 per share (C$13.60
👍️0
MahinAgency MahinAgency 7 months ago
Key Points:

Rating & Price Target: H.C. Wainwright maintains a "Buy" rating for Cardiol Therapeutics (CRDL) with a price target of $9.00.
New Trial: MAVERIC-2 trial aims to assess CardiolRx in recurrent pericarditis (RP) patients post-IL-1 blocker therapy.
Market Advantage: CardiolRx could serve as an earlier treatment alternative, competing with Arcalyst, which costs $300,000 annually.
Strategic Expansion: By targeting unmet needs in the RP market, CardiolRx is positioned to broaden its market potential.
👍️0
MahinAgency MahinAgency 7 months ago
NASDAQ: $CRDL up over 220% year-to-date; analysts raised the price target from $4.50 to $11.00, keeping a "Speculative Buy" rating.

Recently raised $13.5 million to fund developments?
👍️0
MahinAgency MahinAgency 7 months ago
Big coming Next week 💃💃💃💃
👍️0
MahinAgency MahinAgency 7 months ago
NASDAQ: $CRDL
ARCHER trial completed enrollment, with results expected in Q1 2025. Orphan status could lead to $120M peak sales 

Promising early results, potential approval by 2027, targeting $609M peak sales

👍️0
MahinAgency MahinAgency 7 months ago
NASDAQ: $CRDL With about $21 million in cash, the company may consider a small capital raise if new data boosts the stock price, aiming for a target of $10 per share (C$13.60

$CRDL BIG SHORT SQUEEZE 
👍️0
tw0122 tw0122 7 months ago
Chart looking good $2.07 next targets $4
👍️0
glenn1919 glenn1919 7 months ago
CRDL........................https://stockcharts.com/h-sc/ui?s=CRDL&p=W&b=5&g=0&id=p86431144783
👍️0
MahinAgency MahinAgency 7 months ago
NASDAQ: $CRDL sets a 12-month price target of $10, valuing CardiolRx at $9 for recurrent pericarditis and $1 for acute myocarditis, based on projected sales and associated probabilities.
👍️0
MahinAgency MahinAgency 7 months ago
NASDAQ: $CRDL up over 220% year-to-date; analysts raised the price target from $4.50 to $11.00, keeping a "Speculative Buy" rating.

👍️0
MahinAgency MahinAgency 7 months ago
NASDAQ: $CRDL 12-Month Price Target: $10 based on a sum-of-the-parts valuation.

Cardiol had around $21 million in cash at the end of Q1 


👍️0
MahinAgency MahinAgency 7 months ago
NASDAQ: $CRDL
 Cardiol Therapeutics recently reported encouraging outcomes from its Phase II MAvERIC trial of CardiolRx, an ultra-pure oral cannabidiol formulation for recurrent pericarditis.

The 12-month price target is $10
👍️0
MahinAgency MahinAgency 7 months ago
NASDAQ: $CRDL Cardiol Therapeutics sets a 12-month price target of $10, valuing CardiolRx at $9 for recurrent pericarditis and $1 for acute myocarditis, based on projected sales and associated probabilities.
👍️0
MahinAgency MahinAgency 7 months ago
NASDAQ: CRDL is advancing CardiolRx™ for acute myocarditis and recurrent pericarditis, both in Phase II trials. The company raised $13.5 million
👍️0
MahinAgency MahinAgency 7 months ago
NASDAQ: $CRDL CEO Investment: Cardiol CEO David Elsley purchased approximately $100,000 in shares at about $2.03 each, indicating strong personal conviction in the company's potential.
👍️0
MahinAgency MahinAgency 7 months ago
NASDAQ: $CRDL With about $21 million in cash, the company may consider a small capital raise if new data boosts the stock price, aiming for a target of $10 per share (C$13.60
👍️0
MahinAgency MahinAgency 7 months ago
NASDAQ: $CRDL is advancing CardiolRx™ for acute myocarditis and recurrent pericarditis, both in Phase II trials. The company raised $13.5 million

👍️0
MahinAgency MahinAgency 7 months ago
NASDAQ: $CRDL A target of $10 per share (approximately C$13.60) is proposed, indicating a potential upside of over 5x within a year, contingent on strong data readouts for CardiolRx™?
👍️0
MahinAgency MahinAgency 7 months ago
Cardiol Therapeutics sets a 12-month price target of $10, valuing CardiolRx at $9 for recurrent pericarditis and $1 for acute myocarditis, based on projected sales and associated probabilities.
👍️0
MahinAgency MahinAgency 7 months ago
$CRDL Insider Buying: Cardiol CEO David Elsley purchased approximately $100,000 in shares at about $2.03 each
👍️0
MahinAgency MahinAgency 8 months ago
NASDAQ: $CRDL Cardiol Therapeutics sets a 12-month price target of $10, valuing CardiolRx at $9 for recurrent pericarditis and $1 for acute myocarditis, based on projected sales and associated probabilities
👍️0

Your Recent History

NASDAQ
CRDL
Cardiol Therapeutics
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub
United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN Ltd - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads